<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01663207</url>
  </required_header>
  <id_info>
    <org_study_id>Beta Cell - Protocol 1c</org_study_id>
    <nct_id>NCT01663207</nct_id>
  </id_info>
  <brief_title>Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes</brief_title>
  <official_title>Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for the National Institutes of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for the National Institutes of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-year clinical study to improve tools for measuring the function of insulin-producing&#xD;
      beta cells in people with type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A three-year observational study to standardize the meal tolerance and maximum stimulational&#xD;
      tests for measuring beta cell function in the clinical setting. It also aims to improve&#xD;
      methods for the early prediction of the long-term response to an intervention and for&#xD;
      identification of patients at risk for rapid beta cell function deterioration, thereby&#xD;
      enabling future clinical studies that examine diabetes progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>obese individuals with prediabetes</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        obese individuals with prediabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to give informed consent and comply with all study requirements&#xD;
&#xD;
          2. Overweight and obese, generally healthy men and women. Healthy is defined as no&#xD;
             clinically relevant abnormalities identified by a detailed medical history (with the&#xD;
             exception of glucose tolerance, see below), full physical examination, including blood&#xD;
             pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.&#xD;
&#xD;
          3. Glucose Parameters:&#xD;
&#xD;
               1. Fasting plasma glucose ≥100 mg/dL and &lt;126 mg/dL&#xD;
&#xD;
               2. 2h post-OGTT glucose of ≥140 and &lt;200 mg/dL&#xD;
&#xD;
               3. HbA1c&lt;6.5%&#xD;
&#xD;
          4. Women of child-bearing potential are allowed (but must agree to use non-hormonal&#xD;
             contraception and not plan to become pregnant for the duration of the study). Must&#xD;
             agree to maintain the same contraceptive measures throughout the study. Acceptable&#xD;
             contraceptive methods for female subjects of childbearing potential include one of the&#xD;
             following:&#xD;
&#xD;
               -  Abstinence.&#xD;
&#xD;
               -  One (1) of the following methods:&#xD;
&#xD;
                    -  Tubal ligation&#xD;
&#xD;
                    -  Copper-containing intrauterine device (IUD)&#xD;
&#xD;
                    -  Condom AND spermicidal foam/gel/film/cream/suppository&#xD;
&#xD;
                    -  Male partner who has had a vasectomy for at least 6 months.&#xD;
&#xD;
          5. It is required that all male subjects use an acceptable method of contraception (as&#xD;
             outlined below), starting from the first dose of study medication and continuing for&#xD;
             at least 28 days after the last dose of study drug:&#xD;
&#xD;
               1. Abstinence&#xD;
&#xD;
               2. A condom AND one of the following:&#xD;
&#xD;
                    -  Vasectomy for more than 6 months.&#xD;
&#xD;
                    -  Female partner who meets one of the following conditions:&#xD;
&#xD;
                         -  Has had a tubal ligation, hysterectomy, or bilateral oophorectomy; or&#xD;
&#xD;
                         -  Is post menopausal (menopause is defined as over the age of 60 years,&#xD;
                            or between 45 and 60 years being amenorrheic for at least 2 years with&#xD;
                            plasma (FSH) level &gt; 30 UI/L) or&#xD;
&#xD;
                         -  Or for female partners of the male participants, in addition to&#xD;
                            hysterectomy, oophorectorectomy, or post-menopausal status, that the&#xD;
                            use of a spermicidal gel or foam will constitute adequate protection in&#xD;
                            conjunction with use of a condom by the male.&#xD;
&#xD;
          6. BMI 27-40; stable weight (less than 3% change in past 3 months) Age Range: 30-65&#xD;
&#xD;
          7. No history of diabetes mellitus&#xD;
&#xD;
          8. Other conditions may be allowed, if medically stable and controlled for at least four&#xD;
             weeks within acceptable limits, including: hypertension, dyslipidemia, osteoarthritis,&#xD;
             osteoporosis&#xD;
&#xD;
          9. Smokers allowed, but must be able to participate on inpatient stay and not smoke&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects presenting with any of the following will not be included in the study:&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic,&#xD;
             neoplastic, or allergic or clinical findings at Screening (seasonal allergies OK).&#xD;
&#xD;
          2. Any condition possibly affecting absorption (eg, gastrectomy, malabsorption syndromes,&#xD;
             abdominal surgery other than appendectomy, cholecystectomy or hysterectomy).&#xD;
&#xD;
          3. Use of unacceptable medications&#xD;
&#xD;
          4. A positive urine drug screen.&#xD;
&#xD;
          5. History of regular alcohol consumption exceeding 7 drinks/week for females or 14&#xD;
             drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer&#xD;
             or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.&#xD;
&#xD;
          6. Treatment with an investigational drug within 30 days or 5 half-lives preceding the&#xD;
             first dose of study medication.&#xD;
&#xD;
          7. 12 lead ECG demonstrating QTc &gt;450 msec at Screening for males, 470 msec for females.&#xD;
             If QTc exceeds 450/470 msec, the ECG should be repeated two more times and the average&#xD;
             of the three QTc values should be used to determine the subject's eligibility. An ECG&#xD;
             with evidence for possible old myocardial infarction will need to have prior ECGs to&#xD;
             document stability of finding.&#xD;
&#xD;
          8. Supine blood pressure &gt;=140 mm Hg (systolic) or 90 mm Hg (diastolic), on a single&#xD;
             measurement. If elevated, confirm by a single repeat, following at least 10 minutes of&#xD;
             rest.&#xD;
&#xD;
          9. Screening serum alanine transaminase (ALT) or serum aspartate transaminase (AST)&#xD;
             greater than 2X the upper limit of the laboratory reference range.&#xD;
&#xD;
         10. Elevated fasting triglycerides at screening (&gt;500 mg/dL), confirmed by a single repeat&#xD;
             if deemed necessary.&#xD;
&#xD;
         11. Pregnant or nursing females; inability to use effective contraception.&#xD;
&#xD;
         12. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.&#xD;
&#xD;
         13. Participation in a clinical biomedical research study within prior two months may be&#xD;
             excluded, depending on study type and details.&#xD;
&#xD;
         14. History of sensitivity to heparin or heparin-induced thrombocytopenia, if utilized by&#xD;
             the site for blood draws.&#xD;
&#xD;
         15. Unwilling or unable to comply with directions and procedures described in this&#xD;
             protocol.&#xD;
&#xD;
         16. Subject is the Investigator or a sub-Investigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff, or a relative of study personnel directly involved&#xD;
             with the conduct of the study.&#xD;
&#xD;
         17. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the subject&#xD;
             inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Atiee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Development Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Development Solutions, Gault Lane</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>August 9, 2012</study_first_submitted>
  <study_first_submitted_qc>August 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2012</study_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>beta cell function</keyword>
  <keyword>meal tolerance test</keyword>
  <keyword>maximum stimulation test</keyword>
  <keyword>method standardization</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>prediabetes</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

